Genetic Disorder Focused Soleno Therapeutics' Stock Is Trading 4X Today - Here's Why?
Portfolio Pulse from Vandana Singh
Soleno Therapeutics Inc (NASDAQ:SLNO) released top-line results from a long-term treatment study of DCCR for Prader-Willi syndrome (PWS). The results showed a significant improvement in hyperphagia-related behaviors and overall severity of illness in patients treated with DCCR compared to the placebo group. Following the news, SLNO shares surged 409.3% in the premarket session.
September 26, 2023 | 1:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Soleno Therapeutics' stock price surged following the release of positive results from a long-term treatment study of DCCR for Prader-Willi syndrome.
The significant improvement in hyperphagia-related behaviors and overall severity of illness in patients treated with DCCR, as shown in the study results, has led to a surge in Soleno Therapeutics' stock price. This indicates a positive market reaction to the news.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100